Table 4.
Change levels of inflammatory factors,hemorheology,lipid and immunologic factors in vivo (n=45 each group).
| Groups | Inflammatory factors | |||||||
|---|---|---|---|---|---|---|---|---|
| TNF- (ng/ml) | IL-6 (μmol/L) | IL-8 (μmol/L) | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 12.31 ± 3.1 | 3.48 ± 1.12 | 107.39 ± 31.02 | 62.71 ± 39.47 | 112.92 ± 81.66 | 61.67 ± 31.94 | ||
| Control | 12.85 ± 2.8 | 15.78 ± 2.93 | 106.91 ± 18.40 | 103.54 ± 22.74 | 111.74 ± 54.83 | 114.58 ± 89.43 | ||
| P value | 0.76 | 0.00 | 1.00 | 0.00 | 1.00 | 0.00 | ||
| Groups | Hemorheological indices (mPa.s) | |||||||
| Low cut whole blood viscosity (1/S) | Medium cut whole blood viscosity (30/S) | High cut whole blood viscosity (200/S) | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 17.55 ± 1.5 | 16.28 ± 1.49 | 4.83 ± 0.13 | 4.66 ± 0.21 | 3.94 ± 0.12 | 3.67 ± 0.21 | ||
| Control | 17.65 ± 1.74 | 17.86 ± 1.68 | 4.81 ± 0.18 | 4.86 ± 0.19 | 3.92 ± 0.15 | 3.99 ± 0.16 | ||
| P value | 1.00 | 0.00 | 0.95 | 0.00 | 0.94 | 0.00 | ||
| Groups | Hemorheological indices (mPa.s) | |||||||
| plasma viscosity | Reduced viscosity of whole blood (high cut) | Reduced viscosity of whole blood (low cut) | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 1.55 ± 0.14 | 1.39 ± 0.11 | 5.53 ± 0.39 | 5.37 ± 0.21 | 41.43 ± 4.06 | 39.39 ± 3.75 | ||
| Control | 1.55 ± 0.11 | 1.57 ± 0.1 | 5.53 ± 0.38 | 5.61 ± 0.41 | 41.94 ± 3.95 | 42.18 ± 3.95 | ||
| P value | 0.99 | 0.000 | 0.99 | 0.009 | 0.93 | 0.005 | ||
| Groups | Lipid indices (mmol/L) | |||||||
| TC | TG | LDL | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 5.05 ± 0.6 | 4.48 ± 0.57 | 2.75 ± 0.54 | 1.55 ± 0.21 | 3.17 ± 0.29 | 2.84 ± 0.26 | ||
| Control | 4.91 ± 0.67 | 4.96 ± 0.67 | 2.66 ± 0.56 | 2.82 ± 0.39 | 3.13 ± 0.34 | 3.19 ± 0.26 | ||
| P value | 0.72 | 0.002 | 0.78 | 0.000 | 0.91 | 0.00 | ||
| Groups | Lipid indices (mmol/L) | T cell immunologic indices (%) | ||||||
| HDL | CD3 | CD4 | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 1.57 ± 0.16 | 1.71 ± 0.15 | 59.94 ± 6.85 | 64.47 ± 6.00 | 36.29 ± 7.59 | 39.59 ± 6.36 | ||
| Control | 1.55 ± 0.14 | 1.52 ± 0.17 | 60.6 ± 6.91 | 59.2 ± 6.81 | 36.33 ± 8.51 | 32.13 ± 6.61 | ||
| P value | 0.93 | 0.00 | 0.97 | 0.001 | 0.99 | 0.00 | ||
| Groups | T cell immunologic indices (%) | B cell immunologic indices | ||||||
| CD8 | CD4/CD8 | IgM (g/L) | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 24.06 ± 7.85 | 23.18 ± 7.64 | 1.72 ± 0.69 | 1.91 ± 0.73 | 1.08 ± 0.39 | 1.39 ± 0.43 | ||
| Control | 24.47 ± 7.42 | 25.47 ± 7.16 | 1.81 ± 1.22 | 1.38 ± 0.56 | 1.06 ± 0.3 | 1.09 ± 0.37 | ||
| P value | 0.99 | 0.47 | 0.96 | 0.016 | 0.99 | 0.001 | ||
| Groups | B cell immunologic indices (g/L) | Complement indices (ng/ml) | ||||||
| IgA | IgG | C3 | ||||||
| Start | 6 months | Start | 6 months | Start | 6 months | |||
| Treatment | 1.73 ± 0.43 | 2.17 ± 0.47 | 10.91 ± 1.46 | 12.25 ± 1.55 | 0.88 ± 0.15 | 0.93 ± 0.16 | ||
| Control | 1.73 ± 0.48 | 1.8 ± 0.45 | 10.85 ± 1.6 | 11.04 ± 1.62 | 0.89 ± 0.14 | 0.88 ± 0.14 | ||
| P value | 0.99 | 0.001 | 0.99 | 0.002 | 0.99 | 0.38 | ||
| Groups | Complement indices (ng/ml) | |||||||
| C4 | ||||||||
| Start | 6 months | |||||||
| Treatment | 0.22 ± 0.05 | 0.27 ± 0.06 | ||||||
| Control | 0.22 ± 0.06 | 0.23 ± 0.06 | ||||||
| P value | 0.99 | 0.007 | ||||||